Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
ESC 25 Guidelines Discussion: Management of Cardiovascular Disease and Pregnancy
Author(s): Harriette Van Spall , Julie De Backer Added: 2 months ago
ESC Congress 2025 - Late-breaker host Dr Harriette Van Spall (McMaster University, CA) joins Prof Julie De Backer (University Hospital Ghent, BE) to discuss the newly released 2025 ESC Guidelines for the Management of Cardiovascular Disease in Pregnancy. Together, they highlight key updates, critical advances in maternal cardiovascular care, and evidence-based recommendations tailored for this… View more

CV Disease in Special Populations

Guidelines & Statements
Secondary Prevention of Atherosclerotic Cardiovascular Disease
Author(s): Madelyn Hurwitz , Olayinka J Agboola , Abhishek Gami , et al Added: 7 months ago

Prevention & Chronic Conditions
Diversity in Cardiovascular Disease: Are we Failing the General Population?
Author(s): Martha Gulati Added: 1 year ago
In this video series recorded at ACC 2024 in Atlanta, US, Prof Martha Gulati (Cedars-Sinai Smidt Heart Institute, Los Angeles, US) unveils pivotal data from four posters addressing the pressing issue of inequality in cardiology and healthcare. Gain a deeper understanding of personalised treatment approaches, recognise the importance of inclusivity in clinical trials and confront disparities in… View more

CV Disease in Special Populations
HsCRP in ASCVD
Author(s): Adhya Mehta , Roger S Blumenthal , Ty J Gluckman , et al Added: 8 months ago

Prevention & Chronic Conditions
Author(s): Evan A Stein Added: 1 year ago
ACC.24 — We are joined onsite by investigator, Dr Evan A Stein (Medpace Reference Laboratories, US) to discuss the findings from the LIBerate-CVD trial (NCT04797247).LIBerate-CVD investigated LDL-C reductions in a cohort of 900 patients with cardiovascular diseases and hyper-LDL-cholesterol treated with 300mg subcutaneous Lerodalcibep as compared to placebo across a 52-week treatment period… View more

Prevention & Chronic Conditions
ESC 24: EPIC-CAD: Edoxaban vs Dual Antiplatelet Therapy in AF & CAD
Author(s): Gi-Byoung Nam , Min Soo Cho Added: 1 year ago
ESC Congress 2024 — Edoxaban monotherapy significantly improves outcomes in high-risk patients with CAD and atrial fibrillation.Investigators, Dr Gi-Byoung Nam (Ulsan University Hospital, Ulsan, SK) and Dr Min Soo Cho (Asan Medical Center, Seoul, SK) join us to discuss the key findings from the EPIC-CAD trial (NCT03718559).This Korean multi-centre, open-labelled, randomised controlled study… View more

Anticoagulation

Electrophysiology & Arrhythmia
TCT 2025: Short-CUT: Lithotripsy Vs Cutting Balloon for CAD
Author(s): Suzanne J Baron Added: 1 month ago
TCT 2025 — Dr Suzanne J Baron (Massachusetts General Hospital, US), principal investigator of the Short-CUT trial (NCT06089135; Baim Institute for Clinical Research), joins us to discuss this investigator-initiated, multicentre randomized controlled study.The trial enrolled 410 patients with moderate to severe coronary artery calcification across up to 22 international sites. Eligible… View more

Intervention
EuroPCR 24: Influence of Pathophysiological Patterns of CAD on PCI
Author(s): Carlos Collet Added: 1 year ago
EuroPCR 24 - We are joined onsite by Dr Carlos Collet (OLV Hospital Aalst, BE) to discuss the findings from a study analysing the influences of the pathophysiological patterns of coronary artery disease on the safety and efficacy of PCI.The study aimed to assess the capacity of pullback pressure gradient (PPG) in predicting post-PCI fractional flow ratio (FFR), as well as the impact of PPG on… View more

Intervention
AHA 25 Late-breaking Discussion: The VESALIUS-CV Trial
Author(s): Erin A Bohula , Harriette Van Spall Added: 2 weeks ago
AHA Scientific Sessions 2025 – Late-breaker host Dr Harriette Van Spall (McMaster University, CA) is joined by Dr Erin A Bohula (Brigham & Women's Hospital, US) to discuss the primary results of the VESALIUS-CV trial, a large-scale, phase 3, double-blind, randomised, placebo-controlled study sponsored by Amgen.The VESALIUS-CV trial (NCT03872401) evaluated the impact of evolocumab, a PCSK9… View more

MI/ACS

Prevention & Chronic Conditions
ESC HFA 25: SCD-PROTECT
Author(s): Johann Bauersachs Added: 6 months ago
ESC HF 25 - SCD-PROTECT shows high risk of sudden cardiac arrest (SCA) and sudden cardiac death (SCD) during early medical therapy optimization for reduced LVEF in patients with new non-ischemic cardiomyopathy or MI/CAD.Prof Johann Bauersachs (Hannover Medical School, Hannover, DE) discusses findings from the SCD–PROTECT study, an investigation of sudden cardiac arrest in patients with newly… View more

Heart Failure

MI/ACS